Defects in Interferon Signaling in Melanoma Patients
Author Information
Author(s): Rebecca J Critchley-Thorne, Ning Yan, Serban Nacu, Jeffrey Weber, Susan P Holmes, Peter P Lee
Primary Institution: Stanford University
Hypothesis
What are the molecular mechanisms of immune dysfunction in patients with metastatic melanoma?
Conclusion
Defects in interferon signaling are significant contributors to immune dysfunction in melanoma patients.
Supporting Evidence
- 17 of 25 significantly altered genes in T cells and B cells from melanoma patients are interferon-stimulated genes.
- The median percentage of lymphocytes that phosphorylate STAT1 in response to interferon-α was significantly reduced in melanoma patients compared to healthy controls.
- Two subgroups of patients with melanoma were identified: IFN-responsive (33%) and low-IFN-response (66%).
- Functional abnormalities in T cells from low-IFN-response patients included decreased expression of activation markers and reduced survival following stimulation.
Takeaway
The study found that patients with melanoma have problems with their immune cells that make it harder for them to fight cancer, especially when it comes to a protein called interferon.
Methodology
Gene expression profiles of sorted lymphocytes from melanoma patients were compared to healthy controls using microarray analysis and validated with quantitative PCR.
Potential Biases
Potential bias due to the selection of patients and controls.
Limitations
The study focused on a small sample size and may not represent all melanoma patients.
Participant Demographics
12 patients with metastatic melanoma (6 male, 6 female) and 12 age- and gender-matched healthy controls.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI, 0.98 to 33.35
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website